Circulating microRNA as a Novel Biomarker for Pulmonary Arterial Hypertension Due to Congenital Heart Disease
Circulating microRNA as a Novel Biomarker for Pulmonary Arterial Hypertension Due to Congenital Heart Disease
复制标题
DOI：
10.1007/s00246-016-1487-3
复制
发表时间：
2017-01-01
影响因子：
1.6
通讯作者：
Li, Shoujun
中科院分区：
文献类型：
--
作者：
Chen, Weidan;Li, Shoujun
循环 microRNA (miRNA) 最近已被证明是多种疾病的实用且有前景的生物标志物。然而，尚未发现循环 miRNA 是先天性心脏病引起的肺动脉高压 (PAH) 的生物标志物。 PAH 的定义是静息时平均肺动脉压 (mPAP) >25 mmHg。血样和肺组织采集自室间隔缺损（VSD）导致的严重 PAH 患者（PAH 组，mPAP >45 mmHg，n=14）和 VSD 但非 PAH 患者（对照组，mPAP）
Circulating microRNAs (miRNAs) have recently been indicated as practical and promising biomarkers for various diseases. However, circulating miRNAs have not been found to be biomarkers for pulmonary arterial hypertension (PAH) due to congenital heart disease. PAH is defined by a mean pulmonary arterial pressure (mPAP) >25 mmHg at rest. Blood samples and lung tissues were collected from patients with severe PAH due to ventricular septal defect (VSD) (PAH group, mPAP >45 mmHg, n=14) and patients with VSD but non-PAH (control group, mPAP